[Results of a multicentric clinical study of mezlocillin in Japan (author's transl)].

Abstract

In a clinical trial including 701 patients 6-((R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) proved effective in the treatment of severe infections. It showed a particularly high efficacy in septicaemia and endocarditis and in purulent meningitis. In cases unresponsive to previous treatment with other antibiotics mezlocillin was effective in about two-thirds of the cases. Side effects were slight and of the same nature as those accompanying other penicillins.

• Authors: R Fujii
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 29 Issue 12a Pg. 2005-8 ( 1979) ISSN: 0004-4172 [Print] Germany
• Vernacular Title: Ergebnisse multizentrischer klinischer Prüfungen mit Mezlocillin in Japan.
• PMID: 396930 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Penicillins
• Mezlocillin

Topics

• Adolescent
• Adult
• Aged
• Aging
• Anti-Bacterial Agents (therapeutic use)
• Bacterial Infections (drug therapy, microbiology, pathology)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Female
• Humans
• Infant
• Japan
• Male
• Mezlocillin
• Middle Aged
• Penicillins (adverse effects, metabolism, therapeutic use)